Improving Drug Design: Considerations for the Structural Modification Process

Biotransformation and Metabolite Elucidation of Xenobiotics

Volumn , Issue , 2010, Pages 163-216

  Nassar, Ala F ^a  

^a BRANDEIS UNIVERSITY   (United States)

Author keywords

Drug design improvement for structural modification process; Reactive intermediate theory and idiosyncratic reactions toxic effects; Toxicity problems, idiosyncratic conditions late stages of drug development

Indexed keywords

EID: 84888730833     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470890387.ch4     Document Type: Chapter

References (117)

1. Ariens EJ et al. 1982 Strategy in Drug Research Amsterdam, Elsevier Scientifi c Publishing Company
2. Bailey MJ et al. 1996 Chemical and immunochemical comparison of protein adduct formation of four carboxylate drugs in rat liver and plasma Chem Res Toxicol 9, 659-666
3. Bakke OM et al. 1995 Drug safety discontinuations in the United Kingdom, the United States and Spain from 1974 through 1993: A regulatory perspective Clin Pharmacol Ther 58 ( 1 ): 108-117
4. Bergeron MG., Bernier M., L ' Ecuyer J 1992 In vitro activity of clarithromycin and its 14 - hydroxy - metabolite against 203 strains of Haemophilus infl uenzae Infection 20, 164-167
5. Blanchard SG et al. 1998 Discovery of bioavailable inhibitors of secretory phospholipase A2 Pharm Biotechnol 11, 445-463
6. Bodor N 1984 Soft drugs: Principles and methods for the design of safe drugs Med Res Rev 4, 449-469
7. Bodor N., Buchwald P 2000 Soft drug design: General principles and recent applications Med Res Rev 20, 58-101
8. Bodor N., Buchwald P 2004 Designing safer (soft) drugs by avoiding the formation of toxic and oxidative metabolites Mol Biotechnol 26, 123-132
9. Bodor N., Kaminski JJ 1980 Soft drugs: 2. Soft alkylating compounds as potential antitumor agents J Med Chem 23, 566-569
10. Borges N et al. 2000 Tolcapone - related liver dysfunction: Implications for use in Parkinson ' s disease therapy Drug Saf 26 ( 11 ): 743-747
11. Bos H., Henning RH., De Boer E., Tiebosch AT., De Jong PE., De Zeeuw D., Navis G 2002 Addition of AT1 blocker fails to overcome resistance to ACE inhibition in adriamycin nephrosis Kidney Int 61, 473-480
12. Bouska JJ et al. 1997 Improving the in vivo duration of 5 - lipoxygenase inhibitors: application of an in vitro glucuronosyltransferase assay Drug Metab Dispos 25 ( 9 ): 1032-1038
13. Bouska JJ., Bell RL., Goodfellow CL., Stewart AO., Brooks CD., Carter GW 1997 Improving the in vivo duration of 5 - lipoxygenase inhibitors: Application of an in vitro glucuronosyltransferase assay Drug Metab Dispos 25, 1032-1038
14. Buhl AE., Waldon DJ., Baker CA., Johnson GA 1990 Minoxidil sulfate is the active metabolite that stimulates hair follicles J Invest Dermatol 95, 553-557
15. Burgey CS et al. 2003 Metabolism - directed optimization of 3 - aminopyrazinone acetamide thrombin inhibitors: Development of an orally bioavailable series containing P1 and P3 pyridines J Med Chem 46, 461-473
16. Burkhardt O., Borner K., Stass H., Beyer G., Allewelt M., Nord C., Lode H 2002 Single -and multiple - dose pharmacokinetics of oral moxifl oxacin and clarithromycin, and concentrations in serum, saliva and faeces Scand J Infect Dis 34, 898-903
17. Coleman MD et al. 1994 Reduction of dapsone hydroxylamine to dapsone during methaemoglobin formation in human erythrocytes in vitro. IV: Implications for the development of agranulocytosis Biochem Pharmacol 48 ( 7 ): 1349-1354
18. Cribb AE et al. 1992 Sulfamethoxazole is metabolized to the hydroxylamine in humans Clin Pharmacol Ther 51, 522-526
19. Dabernat H., Delmas C., Seguy M., Fourtillan JB., Girault J., Lareng MB 1991 The activity of clarithromycin and its 14 - hydroxy metabolite against Haemophilus infl uenzae., determined by in - vitro and serum bactericidal tests J Antimicrob Chemother 27, 19-30
20. Dieckhaus CM et al. 2002 Mechanisms of idiosyncratic drug reactions: The case of felbamate Chem Biol Interact 142 ( 1-2 ): 99-117
21. Dragovich P et al. 2003 Structure - based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors: 8. Pharmacological optimization of orally bioavailable 2 - pyridone - containing peptidomimetics J Med Chem 46 ( 21 ): 4572-4585
22. Ehrnebo M., Nilsson SO., Boreus LO 1979 Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man J Pharmacokinet Biopharm 7, 429-451
23. Ensink JM., Vulto AG., van Miert AS., Tukker JJ., Winkel MB., Fluitman MA 1996 Oral bioavailability and in vitro stability of pivampicillin, bacampicillin, talampicillin, and ampicillin in horses Am J Vet Res 57, 1021-1024
24. Evans DC 2004 Drug - protein adducts: An industry perspective on minimizing the potential for drug bioactivation in drug discovery and development Chem Res Toxicol 17 ( 1 ): 3-16
25. Fan PW et al. 2001 Bioactivation of tamoxifen to metabolite E quinone methide: Reaction with glutathione and DNA Drug Metab Dispos 29, 891-896
26. Fromigue O., Lagneaux L., Body JJ 2000 Bisphosphonates induce breast cancer cell death in vitro J Bone Miner Res 15, 2211-2221
27. Garceau Y., Davis I., Hasegawa J 1978 Plasma propranolol levels in beagle dogs after administration of propranolol hemisuccinate ester J Pharm Sci 67, 1360-1363
28. Genin M et al. 1996 Synthesis and bioactivity of novel bis(heteroaryl)piperazine reverse transcriptase inhibitors: Structure - activity relationships and increased metabolic stability of novel substituted pyridine analogs J Med Chem 39 ( 26 ): 5267-5275
29. Godessart N et al. 1999 Role of COX - 2 inhibition on the formation and healing of gastric ulcers induced by indomethacin in the rat Adv Exp Med Biol 469, 157-163
30. Gorrod JW., Whittesea CMC., Lam SP 1991 Trapping of reactive intermediates by incorporation of 14C - sodium cyanide during microsomal oxidation Adv Exp Med Biol 283, 657-664
31. Greene N et al. 2002 Computer systems for the prediction of toxicity: An update Adv Drug Deliv Rev 54 ( 3 ): 417-431
32. Gupta AK et al. 1998 Severe neutropenia associated with oral terbinafi ne therapy J Am Acad Dermatol 38, 765-767
33. Grillo MP et al. 2001 Effect of alpha - fl uorination of valproic acid on valproyl - S - acyl -CoA formation in vivo in rats Drug Metab Dispos 29, 1210-1215
34. Haack MJ et al. 2003 Toxic rise of clozapine plasma concentrations in relation to infl ammation Eur Neuropsychopharmacol 13 ( 5 ): 381-385
35. Halsey JP et al. 1982 Benoxaprofen: Side - effect profi le in 300 patients Br Med J (Clin Res Ed) 284, 1365-1368
36. Huang F., Browne CE., Wu WM., Juhasz A., Ji F., Bodor N 2003 Design, pharmacokinetic, and pharmacodynamic evaluation of a new class of soft anticholinergics Pharm Res 20, 1681-1689
37. Humphrey MJ., Smith DA 1992 Role of metabolism and pharmacokinetic studies in the discovery of new drugs - Present and future perspectives Xenobiotica 22 ( 7 ): 743-755
38. Humphreys WG., Obermeier MT., Barrish JC., Chong S., Marino AM., Murugesan N., Wang - Iverson D., Morrison RA 2003 Application of structure - metabolism relationships in the identification of a selective endothelin A antagonist, BMS - 193884, with favourable pharmacokinetic properties Xenobiotica 33, 1109-1123
39. Hussain MA., Koval CA., Myers MJ., Shami EG., Shefter E 1987 Improvement of the oral bioavailability of naltrexone in dogs: A prodrug approach J Pharm Sci 76, 356-358
40. Idanpaan - Heikkila J et al. 1977 Agranulocytosis during treatment with chlozapine Eur J Clin Pharmacol 11, 193-198
41. Imai T., Yoshigae Y., Hosokawa M., Chiba K., Otagiri M 2003 Evidence for the involvement of a pulmonary fi rst - pass effect via carboxylesterase in the disposition of a propranolol ester derivative after intravenous administration J Pharmacol Exp Ther 307, 1234-1242
42. Inman WH et al. 1988 Blood disorders and suicide in patients taking mianserin or amitriptyline Lancet 2 ( 8602 ): 90-92
43. Isaacson J et al. 1999 Index of suspicion: Case 3. Acetaminophen overdose Pediatr Rev 20, 309-310., 312-313
44. Jardine DL 2002 Hodgkin ' s disease following methotrexate therapy for rheumatoid arthritis N Z Med J 115 ( 1156 ): 293-294
45. Ju C et al. 1999 Detection of 2 - hydroxyiminostilbene in the urine of patients taking carbamazepine and its oxidation to a reactive iminoquinone intermediate J Pharmacol Exp Ther 288, 51-56
46. Kantharaj E et al. 2003 Simultaneous measurement of drug metabolic stability and identification of metabolites using ion - trap mass spectrometry Rapid Commun Mass Spectrom 17 ( 23 ): 2661-2668
47. Kassahun K et al. 2001 Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission Chem Res Toxicol 14, 62-70
48. Kempf D et al. 1998 Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical effi cacy J Med Chem 41 ( 4 ): 602-617
49. Kopecky EA., Jacobson S., Joshi P., Koren G 2004 Systemic exposure to morphine and the risk of acute chest syndrome in sickle cell disease Clin Pharmacol Ther 75, 140-146
50. Kostiainen R et al. 2003 Liquid chromatography/atmospheric pressure ionization - mass spectrometry in drug metabolism studies J Mass Spectrom 38 ( 4 ): 357-372
51. Kubinyi H et al. 1977 Quantitative structure - activity relationships: 7. The bilinear model, a new model for nonlinear dependence of biological activity on hydrophobic character J Med Chem 20, 625-629
52. Lasser KE et al. 2002 Timing of new black box warnings and withdrawals for prescription medications J Am Med Assoc 287 ( 17 ): 2215-2220
53. Lesko LL et al. 2000 Optimizing the science of drug development: Opportunities for better candidate selection and accelerated evaluation in humans Pharmaceutical Res 14, 1335-1343
54. Li AP et al. 2002 A review of the common properties of drugs with idiosyncratic hepatotoxicity and the " multiple determinant hypothesis " for the manifestation of idiosyncratic drug toxicity Chem Biol Interact 142 ( 1-2 ): 7-23
55. Li J., Uetrecht JP 2010 The danger hypothesis applied to idiosyncratic drug reactions Handb Exp Pharmacol 196, 493-509
56. Liu ZC et al. 1995 Oxidation of 5 - aminosalicylic acid by hypochlorous acid to a reactive iminoquinone. Possible role in the treatment of infl ammatory bowel diseases Drug Metab Dispos 23, 246-250
57. Lin NH et al. 1997 Structure - activity studies on 2 - methyl - 3 - (2(S) - pyrrolidinylmethoxy) pyridine (ABT - 089): an orally bioavailable 3 - pyridyl ether nicotinic acetylcholine receptor ligand with cognition - enhancing properties J Med Chem 40 ( 3 ): 385-390
58. Madden S et al. 1993 An investigation into the formation of stable, protein - reactive and cytotoxic metabolites from tacrine in vitro. Studies with human and rat liver microsomes Biochem Pharmacol 46, 13-20
59. Mann K et al. 1987 Differential effects of a new dibenzo - epine neuroleptic compared with haloperidol. Results of an open and crossover study Pharmacopsychiat 20, 155-159
60. Matzinger P et al. 2002 The danger model: A renewed sense of self Science 296 ( 5566 ): 301-305
61. Merlani G et al. 2001 Fatal hepatoxicity secondary to nimesulide Eur J Clin Pharmacol 57, 321-326
62. Meyboom RHB et al. 2000 An ABC of drug - related problems Drug Saf 22 ( 6 ): 415-423
63. Miyamoto Y et al. 2003 Oxidative stress caused by inactivation of glutathione peroxidase and adaptive responses Biol Chem 384 ( 4 ): 567-574
64. Mohsin SK et al. 2004 Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: A validation study Mod Pathol 17 ( 12 ): 1545-1554
65. Moses PL et al. 1999 Severe hepatotoxicity associated with bromfenac sodium Am J Gastroenterol 94 ( 5 ): 1393-1396
66. Munns AJ et al. 1997 Bioactivation of phenytoin by human cytochrome P450: Characterization of the mechanism and targets of covalent adduct formation Chem Res Toxicol 10, 1049-1058
67. Nassar A - EF 2009 Minimizing the potential for drug bioactivation of drug candidates to success in clinical development In Drug Metabolism Handbook: Concepts and Applications., ed. Nassar A - EF., Hollenberg P., Scatina J Hoboken, NJ, John Wiley & Sons
68. Nassar A - EF et al. 2003a Metabolite characterization in drug discovery utilizing robotic liquid - handling, quadrupole time - of - fl ight mass spectrometry and in - silico prediction Curr Drug Metab 4, 259-271
69. Nassar A - EF et al. 2003b Online hydrogen - deuterium exchange and a tandem quadrupole time - of - fl ight mass spectrometer coupled with liquid chromatography for metabolite identification in drug metabolism J Chromatog Science 41, 398-404
70. Nassar AF et al. 2004a Strategies for dealing with reactive intermediates in drug discovery and development Curr Opin Drug Discov Devel 7, 126-136
71. Nassar A - EF et al. 2004b Strategies for dealing with metabolite elucidation in drug discovery and development Drug Discov Today 9, 317-327
72. Nassar AE et al. 2004c Detecting and minimizing reactive intermediates in R & D Curr Drug Discov July, 20-25
73. Obach RS et al. 1999a Prediction of human clearance of twenty - nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half - life approach and nonspecifi c binding to microsomes Drug 27 ( 11 ): 1350-1359
74. Obach RS et al. 1999b Nonspecifi c binding to microsomes: Impact on scale - up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol Drug Metabolism 25 ( 12 ): 1359-1369
75. Palani A et al. 2002 Synthesis, SAR, and biological evaluation of oximino - piperidino -piperidine amides: 1. Orally bioavailable CCR5 receptor antagonists with potent anti - HIV activity J Medicinal Chemistry 45 ( 14 ): 3143-3160
76. Parrish DD et al. 1997 Activation of CGS 12094 (prinomide metabolite) to 1,4 - benzoquinone by myeloperoxidase: Implications for human idiosyncratic agranulocytosis Fundam Appl Toxicol 35, 197-204
77. Pirmohamed M et al. 1998 Adverse drug reactions Br Med J 316 ( 7140 ): 1295-1298
78. Plumb RS et al. 2003 Use of liquid chromatography/time - of - fl ight mass spectrometry and multivariate statistical analysis shows promise for the detection of drug metabolites in biological fl uids Rapid Commun Mass Spectrom 17 ( 23 ): 2632-2638
79. Prescott LF et al. 1986 Effects of non - narcotic analgesics on the liver Drugs 32 ( 4 ): 129-147
80. Pritsos CA., Constantinides PP., Tritton TR., Heimbrook DC., Sartorelli AC 1985 Use of high - performance liquid chromatography to detect hydroxyl and superoxide radicals generated from mitomycin C Anal Biochem 150 ( 2 ): 294-299
81. Rane A et al. 1977 Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance J Pharmacol Exp Ther 200 ( 2 ): 420-424
82. Reuning RH., Ashcraft SB., Wiley JN., Morrison BE 1989 Disposition and pharmacokinetics of naltrexone after intravenous and oral administration in rhesus monkeys Drug Metab Dispos 17, 583-589
83. Richard AM et al. 1998 Structure - based methods for predicting mutagenicity and carcinogenicity: are we there yet ? Mutat Res 400 ( 1-2 ): 493-507
84. Ruscoe JE et al. 1995 The effect of chemical substitution on the metabolic activation, metabolic detoxication, and pharmacological activity of amodiaquine in the mouse J Pharmacol Exp Ther 273, 393-404
85. Sabbaga J et al. 1993 Acute agranulocytosis after prolonged high - dose usage of intravenous dipyrone - A different mechanism of dipyrone toxicity ? Ann Hematol 66 ( 3 ): 153-155
86. Salama A et al. 1983 The role of metabolite - specific antibodies in nomifensine -dependent immune hemolytic anemia N Engl J Med 313, 469-474
87. Sanders SP., Bassett DJ., Harrison SJ., Pearse D., Zweier JL., Becker PM 2000 Measurements of free radicals in isolated, ischemic lungs and lung mitochondria Lung 178 ( 2 ): 105-118
88. Schuster C., Reinhart WH., Hartmann K., Kuhn M 1999 Angioedema induced by ACE inhibitors and angiotensin II - receptor antagonists: Analysis of 98 cases Schweiz Med Wochenschr 129, 362-369
89. Segel IH et al. 1993 Kinetics of unireactant enzymes In Enzyme Kinetics., ed. Segel IH., 18-89 New York, John Wiley & Sons, Inc
90. Senturk T et al. 1997 Seizures and hepatotoxicity following sulphasalazine administration Rheumatol Int 17 ( 2 ): 75-77
91. Shameem M., Imai T., Otagiri M 1993 An in - vitro and in - vivo correlative approach to the evaluation of ester prodrugs to improve oral delivery of propranolol J Pharm Pharmacol 45, 246-452
92. Shapiro LE et al. 1997 Comparative safety of tetracycline, minocycline, and doxycycline Arch Dermatol 133, 1224-1230
93. Sjövall J., Magni L., Bergan T 1978 Pharmacokinetics of bacampicillin compared with those of ampicillin, pivampicillin, and amoxycillin Antimicrob Agents Chemother 13, 90-96
94. Skjodt NM et al. 1999 Clinical pharmacokinetics and pharmacodynamics of bromfenac Clin Pharmacokinet 36 ( 6 ): 399-408
95. Stearns RA et al. 2002 The pharmacokinetics of a thiazole benzenesulfonamide beta 3 - adrenergic receptor agonist and its analogs in rats, dogs, and monkeys: Improving oral bioavailability Drug Metab Dispos 30, 771-777
96. Stuart - Harris RC et al. 1984 Aminoglutethimide in the treatment of advanced breast cancer Cancer Treat Rep 11, 189-204
97. Tagat JR et al. 2001 Piperazine - based CCR5 antagonists as HIV - 1 inhibitors: II.Discovery of 1 - [(2,4 - dimethyl - 3 - pyridinyl)carbonyl] - 4 - methyl - 4 - [3(S) - methyl - 4 -[1(S) - [4 - (trifl uoromethyl)phenyl]ethyl] - 1 - piperazinyl] - piperidine N1 - oxide (Sch -350634), an orally bioavailable, potent CCR5 antagonist J Medicinal Chemistry 44 ( 21 ): 3343-3346
98. Takeyama N et al. 1993 Oxidative damage to mitochondria is mediated by the Ca(2 ??) -dependent inner - membrane permeability transition Biochem J 15 ( 294 ): 719-725
99. Taylor EW et al. 2002 Accelerating the drug optimization process: identification, structure elucidation, and quantification of in vivo metabolites using stable isotopes with LC/MSn and the chemiluminescent nitrogen detector Anal Chem 74 ( 13 ): 3232-3238
100. Testa B et al. 1990 Drug metabolism and pharmacokinetics: Implications for drug design Acta Pharm Jugosl 40 ( 3 ): 315-350
101. Tettey JN et al. 2001 Enzyme - induction dependent bioactivation of troglitazone and troglitazone quinone in vivo Chem Res Toxicol 14 ( 8 ): 965-974
102. Thompson CD et al. 1996 Synthesis and in vitro reactivity of 3 - carbamoyl - 2 -phenylpropionaldehyde and 2 - phenylpropenal: Putative reactive metabolites of felbamate Chem Res Toxicol 9, 1225-1229
103. Tiller PR et al. 2002 Liquid chromatography/tandem mass spectrometric quantification with metabolite screening as a strategy to enhance the early drug discovery process Rapid Commun Mass Spectrom 16, 1225-1231
104. Timmins GS., Liu KJ., Bechara EJ., Kotake Y., Swartz HM 1999 Trapping of free radicals with direct in vivo EPR detection: a comparison of 5,5 - dimethyl - 1 - pyrroline -N - oxide and 5 - diethoxyphosphoryl - 5 - methyl - 1 - pyrroline - N - oxide as spin traps for HO * and SO4 Free Radic Biol Med 27 ( 3-4 ): 329-333
105. Uetrecht J 2008 Idiosyncratic drug reactions: Past, present, and future Chem Res Toxicol 21 ( 1 ): 84-92
106. Uetrecht JP et al. 1994 Metabolism of vesnarinone by activated neutrophils: implications for vesnarinone - induced agranulocytosis J Pharmacol Exp Ther 270, 865-872
107. Uetrecht JP et al. 1995 Oxidation of aminopyrine by hypochlorite to a reactive dication: Possible implications for aminopyrine - induced agranulocytosis Chem Res Toxicol 8 ( 2 ): 226-233
108. Uetrecht JP et al. 2002 Screening for the potential of a drug candidate to cause idiosyncratic drug reactions Drug Discov Today 5, 832-837
109. Utili R et al. 1977 Dantrolene - associated hepatic injury: Incidence and character J Gastroenterol 72, 610-616
110. Victor F et al. 1997 Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime J Med Chem 40 ( 10 ): 1511-1518
111. Ware JA et al. 1998 Immunochemical detection and identification of protein adducts of diclofenac in the small intestine of rats: Possible role in allergic reactions Chem Res Toxicol 11, 164-171
112. Watt AP 2003 Metabolite identification in drug discovery Curr Opin Drug Discov Devel 6 ( 1 ): 57-65
113. Woosley RL et al. 1978 Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome N Engl J Med 298, 1157-1159
114. Yunis AA et al. 1980 Chloramphenicol toxicity: Pathogenetic mechanisms and the role of the p - NO2 in aplastic anemia Clin Toxicol 17 ( 3 ): 359-373
115. Zhao Z et al. 1996a Bioactivation of 6,7 - dimethyl - 2,4 - di - 1 - pyrrolidinyl - 7H - pyrrolo[2,3 -d]pyrimidine (U - 89843) to reactive intermediates that bind covalently to macromolecules and produce genotoxicity Chem Res Toxicol 9 ( 8 ): 1230-1239
116. Zhao Z et al. 1996b In vitro and in vivo biotransformation of 6,7 - dimethyl - 2,4 - di - 1 -pyrrolidinyl - 7H - pyrrolo[2,3 - D]pyrimidine (U - 89843) in the rat Drug Metab Dispos 24 ( 2 ): 187-198
117. Zhuang ZP et al. 1998. Isoindol- 1- one analogues of 4-(2 '?- methoxyphenyl) - 1 - [2 '?- [N - (2 ??-pyridyl) -p - iodobenzamido]ethyl]pipera zine (p - MPPI) as 5 - HT1A receptor ligands J Med Chem 41 ( 2 ): 157-166